The Cogstate Blog

Gather insights and guidance from the experts in cognitive measurement.

2,000 Preclinical Alzheimer’s Cognitive Composite (PACC) Administrations: Common Rater Errors + Tips for Preclinical AD Trials
September 12, 2023

2,000 Preclinical Alzheimer’s Cognitive Composite (PACC) Administrations: Common Rater Errors + Tips for Preclinical AD Trials

Preclinical Alzheimer’s Cognitive Composite (PACC): Validated Digital Option Reduces Burden for Patients and Clinical Trial Teams
September 12, 2023

Preclinical Alzheimer’s Cognitive Composite (PACC): Validated Digital Option Reduces Burden for Patients and Clinical Trial Teams

Cogstate CBB: Sensitivity to Cognitive Impairment and Connection to Alzheimer’s Disease Biomarkers
September 5, 2023

Cogstate CBB: Sensitivity to Cognitive Impairment and Connection to Alzheimer’s Disease Biomarkers

From Donepezil to Today | Reflections from 20+ Years on the Front Line of Alzheimer’s Disease Science
August 29, 2023

From Donepezil to Today | Reflections from 20+ Years on the Front Line of Alzheimer’s Disease Science

Digit Symbol Substitution Test (DSST): New Digital Version is Sensitive and Low-burden Option for Global Alzheimer’s Disease Trials
April 6, 2023

Digit Symbol Substitution Test (DSST): New Digital Version is Sensitive and Low-burden Option for Global Alzheimer’s Disease Trials

Momentum in Alzheimer’s Disease Research | Scientific and Operational Advancements in Clinical Trials
January 25, 2023

Momentum in Alzheimer’s Disease Research | Scientific and Operational Advancements in Clinical Trials

Evaluating Cognition in Parkinson’s Disease Clinical Trials: 5 Scale Selection Questions
September 20, 2022

Evaluating Cognition in Parkinson’s Disease Clinical Trials: 5 Scale Selection Questions

Central Rating — Benefits and Considerations for CNS Clinical Outcome Assessment
September 12, 2022

Central Rating — Benefits and Considerations for CNS Clinical Outcome Assessment

Building and Identifying Clinically Relevant Change Across the Alzheimer’s Disease Spectrum
August 23, 2022

Building and Identifying Clinically Relevant Change Across the Alzheimer’s Disease Spectrum

Behavioral and Biological Markers in Rare Disease Research: Tandem Approach Increases Sensitivity and Specificity
March 1, 2022

Behavioral and Biological Markers in Rare Disease Research: Tandem Approach Increases Sensitivity and Specificity

Parkinson’s Disease Clinical Trial Services and Resources
April 27, 2021

Parkinson’s Disease Clinical Trial Services and Resources

A New Clinical Global Impression Scale Enables Precise Detection of Severity and Improvement in Angelman Syndrome
March 31, 2021

A New Clinical Global Impression Scale Enables Precise Detection of Severity and Improvement in Angelman Syndrome

Clinical Dementia Rating–Sum of Boxes: A Promising Outcome Measure for Improved Sensitivity to Treatment Efficacy in Future AD Clinical Trials
March 16, 2021

Clinical Dementia Rating–Sum of Boxes: A Promising Outcome Measure for Improved Sensitivity to Treatment Efficacy in Future AD Clinical Trials

Researchers Share Cognitive Go/No-Go Decision-Making Criteria for Alzheimer’s Disease Drug Development
February 8, 2021

Researchers Share Cognitive Go/No-Go Decision-Making Criteria for Alzheimer’s Disease Drug Development

Study Explored the Preferences of Middle-aged and Older Black Adults Completing Cognitive Testing
September 28, 2020

Study Explored the Preferences of Middle-aged and Older Black Adults Completing Cognitive Testing

How can we help you optimize the measurement of brain health?

Contact Our Team
Cogstate
© 2023 Cogstate Ltd.